Hosted on MSN2mon
FDA approves SPRAVATO as first monotherapy for MDD
MDD affects an estimated 21 million adults in the U.S., and about one-third of these patients do not respond to oral antidepressants alone. The approval of SPRAVATO® as a monotherapy provides a ...
Hosted on MSN2mon
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
In the past 60 days, estimates for BioMarin’s earnings per share have increased from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 32.8%. BMRN’s earnings beat ...